Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke

NCT ID: NCT03740971

Last Updated: 2021-05-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1800 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-26

Study Completion Date

2021-04-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current treatment based on evidence-based medicine for acute ischemic stroke mainly includes reperfusion (intravenous thrombolysis, mechanical thrombolysis), anti-platelet and stroke units. About 1/3 patients can obtain good prognosis through intravenous thrombolysis. Good prognosis can be gotten from about 50 percent of patients with big artery disease by mechanical embolization. However, only a small proportion of the population can be treated with restoration perfusion in the time window. The main purpose of antiplatelet therapy is to prevent the recurrence and progression of stroke, and stroke unit is a kind of management mode. How to improve the neurological function of patients has been a hot and difficult problem in clinical practice.

A large number of basic and clinical studies have proved that remote ischemic conditioning (RIC) has protective effect on ischemic stroke. Hahn et al showed that RIC could play a neuroprotective role in cerebral ischemia-reperfusion injury in MCAO model. Other studies have also confirmed that preconditioning RIC has a neuroprotective effect on cerebral ischemia in animal models. One open label study by Hougaard et al shows that RIC can improve the NIHSS score in acute ischemic stroke patients. One recent study found that 300 consecutive days RIC therapy for the patients with symptomatic intracranial atherosclerotic stenosis significantly reduced the recurrence rate of stroke, improved the mRS score and recovered the blood flow in the lesion site. Furthermore, several studies have also shown that RIC can not only improve the neurological function of patients with cerebral infarction after intravenous thrombolysis and mechanical thrombolysis, but also protect the secondary brain injury after carotid stenting. These results suggest that RIC has a neuroprotective effect on ischemic stroke and deserves further study.

Based on the above discussion, this study aims to explore the efficacy and safety of RIC in the treatment of acute moderate ischemic stroke.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Guideline-based therapy+RIC

RIC is given twice a day with 200mmHg pressure.

Group Type EXPERIMENTAL

Remote Ischemic Conditioning treatment

Intervention Type DEVICE

Remote Ischemic Conditioning is given twice a day with 200mmHg pressure.

Guideline-based therapy

Group Type ACTIVE_COMPARATOR

Guideline-based therapy

Intervention Type DRUG

Guideline-based therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Remote Ischemic Conditioning treatment

Remote Ischemic Conditioning is given twice a day with 200mmHg pressure.

Intervention Type DEVICE

Guideline-based therapy

Guideline-based therapy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient age ≥18 years;
2. From onset to treatment ≤ 48 hours;
3. Ischemic stroke confirmed by head CT or MRI;
4. 6≤NIHSS score ≤ 16;
5. Premorbid mRS ≤ 1;
6. Signed informed consent.

Exclusion Criteria

1. Serious neurological deficits before onset ( mRS ≥ 2);
2. The aetiology of cardiogenic embolism, such as rheumatic mitral or aortic stenosis, artificial heart valve, atrial fibrillation, atrial flutter, sick sinus syndrome, left atrial myxoma, left ventricular wall thrombus or valve neoplasm, congestive heart failure, bacterial endocarditis, etc;
3. Uncontrolled severe hypertension (Systolic pressure ≥180 mmHg or diastolic pressure ≥110 mmHg after drug treatment);
4. Subclavian artery stenosis ≥ 50% or subclavian steal syndrome;
5. Intracranial tumor, arteriovenous malformation or aneurysm;
6. Severe abnormalities in coagulation;
7. Any contraindication for remote ischemic adaptation: the upper limb has serious soft tissue injury, fracture or vascular injury, distal upper limb perivascular lesions, etc.;
8. Comorbidity with any serious diseases and life expectancy is less than half a year;
9. Participating in other clinical trials within 3 months;
10. Patients not suitable for this clinical studies considered by researcher;
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

General Hospital of Shenyang Military Region

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hui-Sheng Chen

Department director

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Huisheng Chen, Doctor

Role: STUDY_CHAIR

Neurology Department

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

General Hospital of ShenYang Military Region

Shenyang, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

References

Explore related publications, articles, or registry entries linked to this study.

He XY, Cui Y, Wang JQ, Wang L, Chen HS. Renal Function and Efficacy of Remote Ischemic Conditioning in Acute Moderate Ischemic Stroke: A Post Hoc Analysis of RICAMIS Trial. Brain Behav. 2025 Oct;15(10):e70831. doi: 10.1002/brb3.70831.

Reference Type DERIVED
PMID: 41058191 (View on PubMed)

Zhang XW, Cui Y, Chen HS. Smoking status and the efficacy of remote ischaemic conditioning: a secondary analysis of the RICAMIS trial. Stroke Vasc Neurol. 2025 Aug 19:svn-2025-004349. doi: 10.1136/svn-2025-004349. Online ahead of print.

Reference Type DERIVED
PMID: 40830061 (View on PubMed)

Cui Y, Cui LY, Chi X, Wang Q, Zhang XW, Chen HS. Platelet-to-Neutrophil Ratio and Efficacy of Remote Ischemic Conditioning in Acute Ischemic Stroke. PLoS One. 2025 Jul 3;20(7):e0322037. doi: 10.1371/journal.pone.0322037. eCollection 2025.

Reference Type DERIVED
PMID: 40608686 (View on PubMed)

Cui Y, Wang XH, Shang ZY, Wang L, Chen HS. Baseline neurologic deficit and efficacy of remote ischemic conditioning after acute ischemic stroke: A post hoc analysis of RICAMIS. Neurotherapeutics. 2024 Jan;21(1):e00294. doi: 10.1016/j.neurot.2023.10.004. Epub 2023 Dec 19.

Reference Type DERIVED
PMID: 38241163 (View on PubMed)

Cui Y, Yuan ZM, Liu QY, Wang YJ, Chen HS. Remote Ischemic Conditioning and Outcomes in Acute Ischemic Stroke With Versus Without Large Artery Atherosclerosis. Stroke. 2023 Dec;54(12):3165-3168. doi: 10.1161/STROKEAHA.123.045040. Epub 2023 Oct 18.

Reference Type DERIVED
PMID: 37850359 (View on PubMed)

Chen HS, Cui Y, Li XQ, Wang XH, Ma YT, Zhao Y, Han J, Deng CQ, Hong M, Bao Y, Zhao LH, Yan TG, Zou RL, Wang H, Li Z, Wan LS, Zhang L, Wang LQ, Guo LY, Li MN, Wang DQ, Zhang Q, Chang DW, Zhang HL, Sun J, Meng C, Zhang ZH, Shen LY, Ma L, Wang GC, Li RH, Zhang L, Bi C, Wang LY, Wang DL; RICAMIS Investigators. Effect of Remote Ischemic Conditioning vs Usual Care on Neurologic Function in Patients With Acute Moderate Ischemic Stroke: The RICAMIS Randomized Clinical Trial. JAMA. 2022 Aug 16;328(7):627-636. doi: 10.1001/jama.2022.13123.

Reference Type DERIVED
PMID: 35972485 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

k(2018)43

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.